Smith Salley Wealth Management Buys Shares of 7,308 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Smith Salley Wealth Management purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,308 shares of the biotechnology company's stock, valued at approximately $889,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nkcfo LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth approximately $43,000. Sunbelt Securities Inc. grew its stake in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank increased its position in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 175 shares during the period. UMB Bank n.a. raised its stake in shares of Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in Sarepta Therapeutics in the third quarter valued at $59,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares of the company's stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on SRPT shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a "buy" rating and a $165.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, January 14th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $178.71.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded up $0.94 on Friday, reaching $118.00. The company's stock had a trading volume of 649,119 shares, compared to its average volume of 566,751. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25. The stock's 50-day moving average is $121.61 and its two-hundred day moving average is $129.52. The stock has a market capitalization of $11.27 billion, a P/E ratio of 94.40 and a beta of 0.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.